is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.
Click for full image >>
TG Therapeutics, Inc. Announces Publication in Blood Describing a Novel Complimentary Mechanism of PI3K-delta inhibitor, TGR-1202
TG Therapeutics Announces the Launch of a Phase 1/2 Study of TGR-1202 and Carfilzomib in Patients with Relapsed or Refractory Lymphoma
2 Gansevoort Street, 9th Floor, New York NY 10014 - P:212.554.4484 - Email Us
Web Site Development by Tidal Media Group